Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals Inc.

Insiders have been trading these 5 stocks: (($APLS)), (($OLMA)), (($XCUR)), (($IMVT)) and (($LPSN)). Here is a breakdown of their recent trades and...

Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up

Looking for top-rated stocks to buy now? Recent analyst updates highlight three companies that have earned Strong Buy ratings from Top Wall Street ...

3 ‘Strong Buy’ Stocks to Buy Now, 1/21/2026, According to Top Analysts

Wells Fargo analyst Derek Archila maintained a Buy rating on Apellis Pharmaceuticals today and set a price target of $29.00. Archila covers the Hea...

Wells Fargo Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Apellis Pharmaceuticals (APLS – Research Report), ...

Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Sarepta Therapeutics (SRPT) and Mereo Biopharma Group Plc (MREO)

Wells Fargo analyst Derek Archila maintained a Buy rating on Apellis Pharmaceuticals yesterday and set a price target of $29.00. The company’s shar...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APLS	$23.57	+3.24%	1.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	APLS	$23.57	+3.2%	1.02M
3
4
5
6

APLS

APLS

Get Apellis Pharmaceuticals Inc. Data in Excel

Get Apellis Pharmaceuticals Inc. Data in Excel